Syrian opposition ready for direct talks with government delegation — representativeWorld February 22, 21:56
UN Syria envoy expects no breakthrough at new round of Syria talksWorld February 22, 21:09
Russia opposes sharing responsibility for fate of Middle East refugeesRussian Politics & Diplomacy February 22, 20:36
First woman in space Valentina Tereshkova may meet with Queen Elizabeth IIRussian Politics & Diplomacy February 22, 20:27
Spain’s famous footballer Puyol returns to Russia next week ahead of FIFA 2017, 2018 CupsSport February 22, 20:15
Putin promotes generals to higher military ranks after Syria operationMilitary & Defense February 22, 19:56
Russia, Turkey may discuss purchase of S-400 systems at March talksMilitary & Defense February 22, 19:18
European human rights watchdog welcomes court’s ruling on Russian opposition activistWorld February 22, 18:42
Maslenitsa festival: a week of pancakes and joySociety & Culture February 22, 17:49
WOBURN, Massachusetts, Dec. 16 /PRNewswire/ -- Covaris, Inc. has introduced the truXTRAC FFPE RNA Kit. This newest innovation from Covaris extracts high quality RNA, suitable for Next Gen Sequencing (NGS), from FFPE tissue samples. NGS-quality is achieved by the use of Covaris' patented Adaptive Focused Acoustics® (AFA) Technology matched with an optimized reagent system. The truXTRAC FFPE RNA extraction method utilizes the highly controlled, focused acoustic energy to remove paraffin from Fixed-Formalin, Paraffin-Embedded (FFPE) samples without the use of organic solvents; enabling efficient and rapid tissue rehydration, tissue digestion, crosslink reversal, and nucleic acid release.
As a result of this advanced methodology, the truXTRAC FFPE RNA Kit provides increased yield of high quality RNA which is readily available for complex molecular biology assays. For example, improved amplificability is a key attribute for efficient NGS library construction and the truXTRAC FFPE RNA method results in higher quality sequencing metrics and enables new clinical applications.
Covaris CEO, Jim Laugharn, commented, "Transcriptome analysis is becoming a routine tool for assessing disease progression. Clinical laboratories are relying on FFPE-extracted RNA at a rapidly increasing rate but the poor quality of RNA derived from traditional extraction methods renders it inappropriate for clinical use. The Covaris process for accurate RNA extraction is uniquely positioned to match the sensitivity and analytical requirements of clinical applications, especially for next-generation sequencing."
Clinical tissue samples are often stabilized in FFPE blocks to retain the histology with biochemical analysis being a secondary concern. The extreme formaldehyde fixation and harsh tissue dehydration of FFPE-preserved tissue sections has previously presented a technical challenge to precise, accurate RNA extraction for use in RNA-Seq with NGS. Additionally, the process created lengthy turn-around times and complicated workflows in a clinical laboratory setting. The truXTRAC FFPE RNA Kit from Covaris advances sample preparation technology and provides the reliable, reproducible, and rapid methodology required by clinical laboratories.
Covaris, Inc., Guillaume Durin, 14 Gill Street, Unit H., Woburn, Massachusetts, USA 01801
Tel : +1 781 932 3959